Therapeutic responses in patients with RA grouped by EULAR response criteria were good (23 by DAS28-ESR and 30 by DAS28-CRP), moderate (25 by DAS28-ESR and 19 by DAS28-CRP), and no response (36 by DAS28-ESR and 35 by DAS28-CRP). This evidence concerns the gene CRP and rheumatoid arthritis.